For the first time, we can see how these proteins are organized and how they may be targeted with greater precision.
For four decades, a critical molecular switch governing cell life and death remained structurally invisible, leaving researchers designing cancer and neurological therapies largely in the dark. Scientists at Mayo Clinic have now mapped the complete three-dimensional architecture of protein kinase C beta in human tissue, revealing not only how the enzyme activates but how an existing breast cancer drug silences it through an indirect, previously unrecognized mechanism. This moment belongs to a long tradition in medicine where seeing clearly — truly seeing — transforms what becomes possible, opening a path toward therapies precise enough to find the right target in the right patient.
- A protein implicated in breast cancer, lymphoma, colorectal cancer, and Alzheimer's disease had resisted structural mapping for forty years, leaving drug designers without a reliable blueprint.
- The breakthrough hinged on a subtle but decisive methodological shift — growing the protein in human cells rather than insect cells, preserving its natural behavior in ways prior techniques could not.
- The new structure exposed an unexpected activation mechanism: membrane lipids act as a mechanical lever, physically flipping the enzyme from dormant to active, a process now visible at the atomic level for the first time.
- Structural data also reframed how endoxifen works — not by blocking the protein's active site directly, but by binding elsewhere and triggering the protein's own degradation, a fundamentally different inhibitory logic than any previous PKC drug.
- Mayo Clinic is now extending this structural framework across all ten PKC family members, pursuing a precision medicine future where therapies are matched to specific proteins driving specific diseases in specific patients.
For forty years, protein kinase C beta sat at the center of cancer research like a locked box. Scientists knew PKCβ functioned as a molecular switch controlling cell growth and survival, and that it was implicated in breast cancer, lymphoma, colorectal cancer, and Alzheimer's disease. But without a clear picture of its structure, designing drugs to stop it was like trying to pick a lock in the dark.
Mayo Clinic researchers have now turned on the light. Publishing in Nature Communications, the team led by molecular biologist Matthew Schellenberg mapped the complete three-dimensional structure of human PKCβ — not a simulation or a proxy, but the actual protein as it exists in human tissue. The key was growing the protein in human cells rather than the insect cells conventionally used, a shift that preserved the enzyme's natural properties in ways the older method could not.
The structure revealed how PKCβ activates: lipid membranes inside cells bind to the protein and act as a mechanical lever, shifting it from a closed, dormant state to an open, active one. This mechanism had been theorized for decades. Now it was mapped at the atomic level.
That clarity also reframed how an existing breast cancer drug, endoxifen, actually works. Rather than competing for the protein's active site as most inhibitors do, endoxifen binds elsewhere and stabilizes PKCβ within cellular membranes in a way that triggers the protein's own degradation — an allosteric mechanism distinct from every previous PKC inhibitor. Medical oncologist Matthew Goetz believes this distinction may explain why endoxifen produces biological effects that earlier compounds did not.
The implications reach across an entire protein family. PKC includes ten related members, each with distinct roles in health and disease, and the question of when each should be activated or inhibited has long haunted researchers. The structural framework Mayo Clinic has established now provides a template for investigating each with precision. The team is already planning to extend their analysis to all ten family members, pursuing a future where drugs are designed not just to hit a target, but to hit the right target in the right patient at the right time.
For forty years, a protein sat at the center of cancer research like a locked box. Scientists knew it mattered—protein kinase C beta, or PKCβ, was implicated in breast cancer, lymphoma, colorectal cancer, and neurological diseases like Alzheimer's. They knew it functioned as a molecular switch, controlling whether cells grew, survived, or died. But they could not see it. Not really. They could not see its shape, its moving parts, how it actually worked. Without that vision, designing drugs to stop it was like trying to pick a lock in the dark.
Mayo Clinic researchers have now turned on the light. In a paper published in Nature Communications, they revealed the complete three-dimensional structure of human PKCβ—not a simulation, not a proxy built in insect cells, but the actual protein as it exists in human tissue. The breakthrough came from a deceptively simple shift: instead of manufacturing the protein in insect cells, the team, led by molecular biologist Matthew Schellenberg, grew it in human cells. The difference was profound. The human-produced protein retained its natural properties in ways the traditional method could not capture. For the first time, researchers could see how the enzyme was organized, how it was regulated, and crucially, how it might be stopped.
The structure revealed something unexpected about how PKCβ turns on. When lipid membranes inside cells bind to the protein, they function like a mechanical lever. The enzyme shifts from a closed, dormant state to an open, active one. The membrane lipids trigger a conformational change that exposes the protein's active site—essentially flipping a switch from off to on. This mechanism had been theorized for decades. Now it was visible, mapped, understood at the atomic level.
That structural knowledge immediately illuminated how an existing breast cancer drug, endoxifen, actually works. Researchers had observed that endoxifen inhibited PKCβ, but the mechanism was unclear. The new structural data showed that endoxifen does not compete directly for the protein's active site, as most inhibitors do. Instead, it works through what scientists call an allosteric mechanism—it binds elsewhere on the protein and changes its behavior indirectly. Specifically, endoxifen stabilizes PKCβ within cellular membranes in a way that triggers the protein's degradation. It is a fundamentally different approach from every previous PKC inhibitor tested over the decades. This distinction may explain why endoxifen shows biological effects that earlier compounds did not, according to Matthew Goetz, a medical oncologist at Mayo Clinic's Comprehensive Cancer Center.
The implications extend far beyond PKCβ alone. The PKC family includes ten related proteins, each with distinct roles in health and disease. Some isoforms may promote tumor growth; others may suppress it. The central question that has haunted cancer researchers—when should each protein be activated, and when should it be inhibited?—has remained largely unanswered. The structural framework Mayo Clinic has now established provides a template for investigating each family member with precision. Researchers can now ask which PKC proteins drive specific cancers, which ones might be protective, and how to design drugs that target the right protein in the right disease context.
Mayo Clinic is already moving forward on multiple fronts. The team is studying endoxifen in premenopausal women with estrogen receptor-positive breast cancer, investigating whether its effects on PKCβ contribute to its anticancer activity. Beyond that, the researchers are planning to extend their structural analysis to all ten PKC family members, seeking to understand how each enzyme functions and responds to therapeutic compounds in its own unique way. What began as a forty-year effort to see a single protein may now open the door to an entirely new generation of precision therapies—drugs designed not just to hit a target, but to hit the right target in the right patient at the right time.
Citações Notáveis
For decades, scientists have been trying to understand how these proteins function. These findings create new opportunities to develop more precise therapies for cancer and other diseases.— Matthew Goetz, medical oncologist at Mayo Clinic Comprehensive Cancer Center
By producing the protein in human cells, we were able to obtain high-quality material that enabled us to finally see how this enzyme is organized and regulated.— Matthew Schellenberg, molecular biologist at Mayo Clinic
A Conversa do Hearth Outra perspectiva sobre a história
Why did it take forty years to see this protein's structure? Wasn't the technology available earlier?
The technology existed, but the approach was wrong. Scientists were making PKCβ in insect cells, which is faster and cheaper. But the protein made that way didn't behave like the real thing in human cells. It was like studying a photograph of a dancer instead of watching them move. The breakthrough came from patience and a willingness to do it the harder way.
So they just switched to human cells and suddenly could see it?
Not suddenly. But yes, when they grew it in human cells, the protein retained its natural properties—the way it folds, the way it responds to membranes. That made it stable enough to image at atomic resolution. Sometimes the simplest solution is the one nobody tried because it seemed too obvious.
The drug endoxifen was already being used. Did doctors not know how it worked?
They knew it worked. They didn't know why. It's like knowing a key opens a door without understanding the lock's mechanism. Now they can see that endoxifen doesn't jam the lock—it changes the shape of the door itself, making the protein unstable. That's a completely different strategy than what researchers had been trying for decades.
Does this mean better breast cancer drugs are coming soon?
It means the path is clearer. Mayo is already testing endoxifen in specific patient populations. But the real opportunity is broader—there are ten PKC proteins, and each one might need a different approach. Understanding one opens the door to understanding the others. That's where the precision medicine piece comes in.
Why does it matter that some PKC proteins might suppress tumors while others promote them?
Because if you inhibit the wrong one, you might actually help the cancer grow. Or you might cause harm in healthy cells. The goal is to hit only what needs to be hit. That requires knowing which protein does what in which context. This structure gives researchers the tools to answer those questions.